NauseaANTI-EDNCT07523230
Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department
A study testing Antiemetic Timing in people with Nausea and Emergency Department Patients, run by muzeyyen ataseven at 1 site in Turkey (Türkiye).
Trial summary
Nausea is a common symptom among patients presenting to the emergency department and can negatively affect patient comfort and clinical outcomes. The timing of antiemetic administration may play a critical role in symptom control; however, evidence regarding the optimal timing remains limited. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Nausea, Emergency Department Patients
- What is being tested?
- Antiemetic Timing
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 Feb 2026to 5 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Presentation to the emergency department with nausea (with or without vomiting)
- Receiving antiemetic treatment
- Ability to communicate
- Ability to provide informed consent
- Ability to undergo nausea assessment using a Numeric Rating Scale (NRS) at initial evaluation
Who cannot join
- Altered level of consciousness (unconscious or confused)
- Intubated patients
- Severe psychiatric conditions (e.g., psychosis or delirium)
- Patients in critical condition requiring immediate resuscitation
- Hemodynamic instability
- Inability to communicate (including language barrier or severe hearing/speech impairment preventing scale application)
- Refusal to participate
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul Medipol University Hospital, Emergency Department
Istanbul, 34810
About this study
Official title: The Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department: A Multicenter Interventional Study
Nausea is a common symptom among patients presenting to the emergency department and can negatively affect patient comfort and clinical outcomes. The timing of antiemetic administration may play a critical role in symptom control; however, evidence regarding the optimal timing remains limited. This multicenter interventional study aims to evaluate the effect of early versus delayed antiemetic administration on nausea severity and patient comfort in adult emergency department patients. Participants will be assigned to receive antiemetic treatment either within the first 30 minutes after triage or after 30 minutes. Nausea severity will be assessed using a numeric rating scale, and patient comfort will be evaluated at predefined time points. The findings of this study are expected to contribute to improving symptom management and optimizing clinical practices in emergency care settings.
Read the detailed description
Nausea is a frequently encountered symptom in emergency department (ED) patients and is associated with decreased patient comfort, prolonged ED stay, and reduced satisfaction with care. Timely management of nausea is essential for improving patient outcomes; however, there is limited evidence regarding the impact of antiemetic administration timing on symptom relief and patient comfort. This study is designed as a prospective, multicenter interventional study to evaluate the effect of antiemetic timing on nausea severity and patient comfort in adult ED patients.
Eligible participants will include adult patients presenting to the ED with nausea. Participants will be allocated into two groups based on the timing of antiemetic administration: early administration (within 30 minutes after triage) and delayed administration (after 30 minutes). Antiemetic agents will be administered according to standard clinical practice.
The primary outcome of the study is nausea severity, which will be measured using a validated numeric rating scale. Secondary outcomes include patient comfort levels and changes in nausea over time. Measurements will be obtained at baseline and at predefined time intervals following antiemetic administration.
This study aims to provide evidence on whether early administration of antiemetic therapy leads to improved symptom control and patient comfort compared to delayed administration. The results may inform clinical decision-making and contribute to the development of evidence-based protocols for nausea management in emergency settings.
- Conditions
- Nausea, Emergency Department Patients
- Being tested
- Antiemetic Timing
- Keywords
- Antiemetic, Nausea, Emergency Department, Timing, Patient Comfort, Symptom Management
- Medical subject headings
- Nausea, Emergencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antiemetic TimingBehavioural
The intervention consists of adjusting the timing of routine antiemetic administration in emergency department patients without altering the type or dosage of medication. Participants are assigned to receive antiemetics either within 30 minutes (early group) or after 30 minutes (delayed group) following triage (T0), in accordance with standard clinical care. Outcome measures include nausea severity assessed using a Numeric Rating Scale (NRS, 0-10) at T0, Tpost30, and Tpost60, and comfort level assessed at T0 and Tpost60.
| Study group | Role | What they receive |
|---|---|---|
| Early Antiemetic Group | Experimental | Participants receive routine antiemetic treatment within 30 minutes after triage (T0). Nausea severity is assessed using a Numeric Rating Scale (NRS, 0-10) at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60). Comfort level is evaluated at baseline and 60 minutes using the General Comfort Questionnaire-Short Form. Receives: Behavioral: Antiemetic Timing |
| Delayed Antiemetic Group | Experimental | Participants receive routine antiemetic treatment more than 30 minutes after triage (T0). Nausea severity is assessed using a Numeric Rating Scale (NRS, 0-10) at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60). Comfort level is evaluated at baseline and 60 minutes using the General Comfort Questionnaire-Short Form. Receives: Behavioral: Antiemetic Timing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Nausea Severity
Nausea severity will be assessed using a Numeric Rating Scale (NRS, 0-10). Measurements will be obtained at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60). The primary outcome is the change in nausea severity over time between the early and delayed antiemetic groups.
Measured: Baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60)
Secondary outcomes (1)
Comfort Level
Comfort level will be assessed using the General Comfort Questionnaire-Short Form. Measurements will be obtained at baseline (T0) and 60 minutes (Tpost60). Differences between groups will be analyzed.
Measured: Baseline (T0) and 60 minutes (Tpost60)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start5 Feb 2026
- Primary completion5 Apr 2026
- Study completion5 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NauseaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is designed as a randomized parallel-group trial in which participants are assigned to either an early or delayed antiemetic administration group. The early group receives antiemetic treatment within 30 minutes of triage (T0), while the delayed group receives treatment after 30 minutes. Outcome measures include nausea severity assessed at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60) using a Numeric Rating Scale (NRS), and comfort level assessed at baseline and 60 minutes using the General Comfort Questionnaire-Short Form.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- muzeyyen ataseven
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, muzeyyen ataseven, Istanbul Medipol University Hospital
- Investigators
- Muzeyyen Ataseven, PhD,RN, Principal investigator, Istanbul Medipol University, Faculty of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07523230
- Sponsor's protocol ID
- ED-ANTIMETIC-TIMING
- Acronym
- ANTI-ED
- Status last verified
- Apr 2026
- First submitted
- 4 Apr 2026
- Last updated
- 27 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to privacy and ethical considerations. De-identified data may be available from the corresponding author upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department: A Multicenter Interventional Study
- ClinicalTrials.gov ID
- NCT07523230
- Acronym / sponsor ID
- ANTI-ED / ED-ANTIMETIC-TIMING
- Conditions
- Nausea, Emergency Department Patients
- Keywords
- Antiemetic, Nausea, Emergency Department, Timing, Patient Comfort, Symptom Management
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- muzeyyen atasevenUniversity, hospital or other
- Study start
- 5 Feb 2026 (actual)
- Primary completion
- 5 Apr 2026 (actual)
- Study completion
- 5 Apr 2026 (actual)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Nausea is a common symptom among patients presenting to the emergency department and can negatively affect patient comfort and clinical outcomes. The timing of antiemetic administration may play a critical role in symptom control; however, evidence regarding the optimal timing remains limited. This multicenter interventional study aims to evaluate the effect of early versus delayed antiemetic administration on nausea severity and patient comfort in adult emergency department patients. Participants will be assigned to receive antiemetic treatment either within the first 30 minutes after triage or after 30 minutes. Nausea severity will be assessed using a numeric rating scale, and patient comfort will be evaluated at predefined time points. The findings of this study are expected to contribute to improving symptom management and optimizing clinical practices in emergency care settings.
Detailed description
Nausea is a frequently encountered symptom in emergency department (ED) patients and is associated with decreased patient comfort, prolonged ED stay, and reduced satisfaction with care. Timely management of nausea is essential for improving patient outcomes; however, there is limited evidence regarding the impact of antiemetic administration timing on symptom relief and patient comfort. This study is designed as a prospective, multicenter interventional study to evaluate the effect of antiemetic timing on nausea severity and patient comfort in adult ED patients.
Eligible participants will include adult patients presenting to the ED with nausea. Participants will be allocated into two groups based on the timing of antiemetic administration: early administration (within 30 minutes after triage) and delayed administration (after 30 minutes). Antiemetic agents will be administered according to standard clinical practice.
The primary outcome of the study is nausea severity, which will be measured using a validated numeric rating scale. Secondary outcomes include patient comfort levels and changes in nausea over time. Measurements will be obtained at baseline and at predefined time intervals following antiemetic administration.
This study aims to provide evidence on whether early administration of antiemetic therapy leads to improved symptom control and patient comfort compared to delayed administration. The results may inform clinical decision-making and contribute to the development of evidence-based protocols for nausea management in emergency settings.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- The study is designed as a randomized parallel-group trial in which participants are assigned to either an early or delayed antiemetic administration group. The early group receives antiemetic treatment within 30 minutes of triage (T0), while the delayed group receives treatment after 30 minutes. Outcome measures include nausea severity assessed at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60) using a Numeric Rating Scale (NRS), and comfort level assessed at baseline and 60 minutes using the General Comfort Questionnaire-Short Form.
| Arm | Type | Receives |
|---|---|---|
| Early Antiemetic Group | Experimental | Behavioral: Antiemetic TimingParticipants receive routine antiemetic treatment within 30 minutes after triage (T0). Nausea severity is assessed using a Numeric Rating Scale (NRS, 0-10) at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60). Comfort level is evaluated at baseline and 60 minutes using the General Comfort Questionnaire-Short Form. |
| Delayed Antiemetic Group | Experimental | Behavioral: Antiemetic TimingParticipants receive routine antiemetic treatment more than 30 minutes after triage (T0). Nausea severity is assessed using a Numeric Rating Scale (NRS, 0-10) at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60). Comfort level is evaluated at baseline and 60 minutes using the General Comfort Questionnaire-Short Form. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥18 years
- Presentation to the emergency department with nausea (with or without vomiting)
- Receiving antiemetic treatment
- Ability to communicate
- Ability to provide informed consent
Key exclusion criteria (7 listed)
- Altered level of consciousness (unconscious or confused)
- Intubated patients
- Severe psychiatric conditions (e.g., psychosis or delirium)
- Patients in critical condition requiring immediate resuscitation
- Hemodynamic instability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antiemetic TimingThe intervention consists of adjusting the timing of routine antiemetic administration in emergency department patients without altering the type or dosage of medication. Participants are assigned to receive antiemetics either within 30 minutes (early group) or after 30 minutes (delayed group) following triage (T0), in accordance with standard clinical care. Outcome measures include nausea severity assessed using a Numeric Rating Scale (NRS, 0-10) at T0, Tpost30, and Tpost60, and comfort level assessed at T0 and Tpost60. | Behavioural | Delayed Antiemetic Group, Early Antiemetic Group |
Primary outcome
Change in Nausea Severity
Time frame: Baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60)
Nausea severity will be assessed using a Numeric Rating Scale (NRS, 0-10). Measurements will be obtained at baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60). The primary outcome is the change in nausea severity over time between the early and delayed antiemetic groups.
1 secondary outcome
Comfort Level
Time frame: Baseline (T0) and 60 minutes (Tpost60)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to privacy and ethical considerations. De-identified data may be available from the corresponding author upon reasonable request.
Related trials for Nausea
RecruitingPhase 4
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Nausea With Vomiting Chemotherapy-Induced
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Not yet recruitingPhase 2
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Breast Cancer
RecruitingPhase 2
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Nausea, Vomiting
Not yet recruitingObservational study
Preoperative Gastric Volume and PONV in Pediatric Appendectomy Cases
Postoperative Nausea and Vomiting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Muzeyyen Ataseven, PhD,RN principal investigator
Istanbul Medipol University, Faculty of Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Antiemetic Timing in people with Nausea and Emergency Department Patients, run by muzeyyen ataseven at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Nausea Severity (time frame: Baseline (T0), 30 minutes (Tpost30), and 60 minutes (Tpost60)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026; AzTrials last refreshed its copy on 8 Nov 2026.